Injections, Laser or Surgery for Macular Diseases: How the Retina Team Picks a Path

The door frame gave it away. One morning it looked slightly bent, as if the house had shifted in the night. She closed her left eye, and the frame straightened. She closed her right eye, and it bowed again. Two weeks later she was sitting in a darkened room while a scanner traced the layers of her retina, and a specialist was talking about injections, laser and, possibly, surgery.

Macular disease treatment sounds like a menu, but it is closer to a decision tree. The macula is the tiny central patch of the retina that handles reading, faces and fine detail, and it can be damaged in several different ways: leaking blood vessels, fluid, slow cell loss, a hole, or a wrinkle of scar tissue. Each of those problems calls for a different tool.

What follows is how retina teams actually think through the choice, what the evidence supports, and what to expect once a path is chosen.

What counts as macular disease, and why the label shapes the treatment

People often arrive at a retina clinic with one phrase in mind: macular degeneration. In practice, the macula can fail in at least half a dozen distinct ways, and the treatment conversation starts by naming the right one.

Age-related macular degeneration (AMD) is the most common. It comes in two broad forms. Dry AMD is a slow thinning of the light-sensing cells and the layer that feeds them, often with yellowish deposits called drusen. Wet AMD is an aggressive complication in which fragile new blood vessels grow under the macula and leak fluid or blood. The NHS notes that dry AMD is far more common, while wet AMD tends to cause faster loss of central sight.

Other conditions share the same postcode. Diabetic macular edema is swelling caused by leaky vessels damaged by diabetes. Retinal vein occlusion is a blocked drainage vein that floods the macula with fluid. Central serous chorioretinopathy is a pocket of fluid that lifts the macula, often in younger adults under stress or taking steroid medicines. A macular hole is a small full-thickness gap in the center of the retina. An epiretinal membrane is a thin sheet of scar tissue that puckers the surface.

Why does this matter so much? Because the tools do different jobs. Injections calm leaking vessels but cannot close a hole. Laser can seal a leak but cannot restore cells that have already thinned. Surgery can relieve pulling and close a gap, but it does nothing for a vessel that is still leaking. A precise diagnosis is not a formality; it is the first and most consequential treatment decision, and it is made on imaging rather than on symptoms alone.

How the retina team decides on macular disease treatment

Watch a retina specialist read a scan and you will notice they are asking a short list of questions in a fixed order. Is there fluid? Where exactly is it? Is anything pulling on the retina? Is the tissue underneath still alive?

The workhorse answer comes from optical coherence tomography, or OCT, a painless scan that uses light to produce a cross-section of the retina, layer by layer, in seconds. Fluid shows up as dark pockets. Traction shows up as a lifted or tented surface. A hole is unmistakable. Thinning of the outer layers signals atrophy, where cells have already been lost. The Mayo Clinic describes OCT as central to both diagnosing wet AMD and tracking response to treatment.

When the team needs to see the plumbing, they add angiography, a photograph series taken after a dye is injected into an arm vein so that leaking vessels light up. Newer OCT angiography maps blood flow without dye. A wide-field photograph records the rest of the retina, because a vein occlusion or diabetic change elsewhere can alter the plan.

Only then does the pathway branch. Active leakage from new vessels or swelling from diabetes or a blocked vein points toward injections. A discrete leak away from the very center, or certain fluid pockets in central serous disease, may point toward a laser option. A hole, a membrane or persistent pulling points toward surgery. Thinning without fluid points toward monitoring and risk reduction rather than any procedure.

Two people with the same visual acuity can be sent down completely different routes. That is not inconsistency. It is the scan doing its job.

How macular degeneration injections actually work

The idea of a needle near the eye stops most people cold, so it helps to understand what the medicine is doing and what the procedure actually involves.

Wet AMD, diabetic macular edema and vein occlusion share a common driver: a signaling protein called vascular endothelial growth factor, or VEGF, which tells the retina to grow new vessels and makes existing ones leak. Anti-VEGF medicines are antibodies or antibody fragments that bind to VEGF and switch that signal off. With the signal quieted, leaking slows, fluid drains and the swollen macula flattens. Several generic drugs in this class exist, including ranibizumab, aflibercept, bevacizumab and faricimab; which one is used depends on the condition, local approvals and the prescribing clinician, and none of that is a decision for a magazine article.

The injection itself is quick. Numbing drops are applied, the eye surface is cleaned with an antiseptic, and a very fine needle delivers the medicine into the vitreous, the clear gel that fills the eyeball, through the white of the eye a few millimeters from the edge of the iris. Most people report pressure rather than pain. The whole visit, including preparation, is usually measured in minutes rather than hours.

The catch is duration. The drug is gradually cleared, and VEGF production does not stop, so injections are repeated. According to the NHS, treatment typically starts with injections around a month apart and is then spaced out according to how the eye responds, often to every one to three months, for as long as the disease stays active. Retina teams use two common rhythms: a fixed schedule, or a treat-and-extend approach in which the gap is lengthened while the OCT stays dry and shortened if fluid returns. The scan, not the calendar, sets the pace.

Wet vs dry macular degeneration: why one gets injections and the other mostly doesn't

This is the single most common source of confusion in the waiting room. A person with dry AMD hears that a neighbor is having injections and wonders why they are being told to come back in a year.

The answer lies in the mechanism. Injections block VEGF, and VEGF is the engine of wet AMD. In dry AMD there are no leaking new vessels to block. The damage is a slow attrition of retinal cells and the pigment layer beneath them, progressing over years. There is nothing for an anti-VEGF drug to switch off, so giving one would expose the eye to procedure risk with no expected benefit.

What the evidence does support for dry AMD is risk reduction. The Age-Related Eye Disease Studies run by the National Eye Institute at the NIH found that a specific antioxidant and zinc formulation reduced the risk of progression to advanced AMD by about 25 percent over five years in people who already had intermediate disease or advanced disease in one eye. The second study, AREDS2, refined the formula by replacing beta-carotene with lutein and zeaxanthin, partly because beta-carotene raised lung cancer risk in smokers. Whether a supplement is appropriate, and which formulation, is a conversation for the eye clinic, because the benefit was seen only in specific stages of disease.

The late stage of dry AMD, called geographic atrophy, is where the picture is changing. Injectable medicines that block part of the complement system, an arm of immune defense implicated in cell loss, have been approved in some countries. Trials showed slower growth of the atrophic patch on imaging rather than improved sight, and not everyone is a candidate. That distinction, slowing versus restoring, is honest and worth holding on to.

Dry AMD can also convert to wet AMD at any time, which is why monitoring is treatment too.

Where laser still fits in treating the macula

Before injections existed, laser was the main tool for the macula. It has since moved from center stage to a set of specific supporting roles, and knowing those roles explains why one person is offered it and another is not.

Conventional thermal laser works by heating a tiny spot of retina to seal a leaking vessel. The heat also destroys the retinal cells at that spot, which is acceptable at the edge of the macula and unacceptable at the very center, where each cell is precious. For that reason, thermal laser for wet AMD is now reserved for the uncommon situation in which the abnormal vessels sit well away from the central fovea, and even then injections are usually considered first.

In diabetic macular edema, focal laser targeting individual leaking microaneurysms remains an evidence-based option, particularly when swelling spares the center or persists alongside injections. The NIH describes laser as one of the established approaches for diabetic eye disease, often used together with anti-VEGF therapy rather than instead of it.

Photodynamic therapy is a different animal. A light-sensitive drug is infused into a vein, then activated by a low-energy laser aimed at the abnormal vessels, closing them with far less collateral heating. It is used for specific patterns such as polypoidal choroidal vasculopathy, a variant of wet AMD more common in people of Asian heritage, and for chronic central serous chorioretinopathy. Subthreshold or micropulse laser, which stimulates the pigment layer without visible burning, is used in some centers for central serous disease and mild diabetic swelling; the evidence base is smaller and still developing, and it is not appropriate everywhere.

Laser is not obsolete. It is precise, and precision means it fits some anatomies and not others.

When surgery is the right tool: macular holes, membranes and traction

Surgery enters the conversation when the problem is mechanical. No medicine closes a hole, peels a membrane or releases gel that is tugging on the retina.

The operation used for most of these problems is a vitrectomy: removing the vitreous gel through three tiny ports in the white of the eye, usually under local anesthesia with sedation. Once the gel is out, the surgeon can work on the macula under a microscope.

For a macular hole, the surgeon typically peels the internal limiting membrane, the thin innermost layer of the retina, to relieve tangential pulling, then fills the eye with a gas bubble. The bubble presses the edges of the hole together while they heal. The NHS explains that the bubble is gradually absorbed and replaced by the eye’s own fluid over roughly two to eight weeks depending on the gas used, and that some people are asked to keep their head face-down for part of each day in the first days to keep the bubble against the hole.

For an epiretinal membrane, the sheet of scar tissue is lifted off the surface with fine forceps, which reduces the wrinkling that distorts straight lines. Gas is not always needed. For vitreomacular traction, where the gel has partially separated and is pulling the center upward, removing the gel relieves the force directly.

Surgery is occasionally used in wet AMD to clear a large bleed under the macula, sometimes combined with injections, but that is an uncommon rescue rather than a routine path.

The key point for patients: surgery is chosen for anatomy, not for severity. A small hole may be operated on promptly because early closure is linked to better anatomical outcomes, while a heavily leaking eye with no traction will never be sent to the operating room.

Who is usually offered injections, laser or surgery, and who is asked to wait

Being told to wait can feel like being turned away. In retina clinics it is usually a deliberate, evidence-led decision, and it helps to see both sides of the ledger.

Injections are usually offered when imaging shows active fluid from new vessels in wet AMD, from diabetic damage, or from a vein occlusion, and when the tissue beneath still has a reasonable chance of function. People are more often asked to wait, or to be monitored instead, when the fluid is minimal and stable, when scarring has already replaced the retina so that reducing fluid would not improve sight, or when the eye has an active infection on its surface that must clear before any needle goes near it.

Laser is usually offered when there is a discrete leak away from the center, or a specific vessel pattern suited to photodynamic therapy. It is usually withheld when the leak sits under the fovea itself, where treatment damage would cost more than it saves.

Surgery is usually offered for a full-thickness macular hole, a membrane that is measurably distorting vision or worsening on scans, or traction that is not releasing on its own. People are commonly asked to wait when a membrane is mild and not bothering them, since some remain stable for years, or when a very small hole shows signs of closing spontaneously, which the NHS notes can happen with early lesions. General health matters too: uncontrolled blood pressure, unstable diabetes or blood thinners that cannot be paused safely may delay an operation.

Dry AMD without fluid is the largest waiting group of all. Here, waiting is not neglect; it is the correct pathway, coupled with risk reduction and prompt re-referral if anything changes.

Injections, laser or surgery at a glance

A single table cannot replace a scan, but it can show why the same word, macula, leads to such different plans. The timelines below are typical ranges drawn from the NHS and the Mayo Clinic, not promises for any individual eye.

Approach	What it does	Typically considered for	Typical rhythm	Main trade-offs
Anti-VEGF injections	Blocks the signal that drives vessel growth and leakage	Wet AMD, diabetic macular edema, retinal vein occlusion	Monthly at first, then spaced by response, often every one to three months, ongoing	Repeated visits; small risk of infection, pressure rise, retinal detachment
Thermal or focal laser	Seals individual leaking vessels with heat	Leaks away from the center; some diabetic swelling	One or a few sessions, repeatable	Permanent small blind spot at treated site; not for central lesions
Photodynamic therapy	Light-activated drug closes abnormal vessels with little heat	Polypoidal disease, chronic central serous chorioretinopathy	One session, sometimes repeated	Light sensitivity for a few days after the infusion; specialist equipment
Vitrectomy surgery	Removes gel, peels membranes, closes holes with a gas bubble	Macular hole, epiretinal membrane, traction	Single operation; gas absorbs over about two to eight weeks	Cataract progression, positioning demands, no flying while gas is present
Monitoring and risk reduction	Detects change early; slows progression in specific stages	Dry AMD, stable mild membranes	Scheduled reviews plus home self-checks	Requires vigilance; conversion to wet disease can be sudden

Notice that the rows are not ranked. There is no best option in the abstract, only the option that matches what the OCT shows. Many people move between rows over time: a person with dry AMD may convert and begin injections; a person having injections may later need surgery for a cataract that the disease did not cause but that limits the view.

What the following days and weeks usually look like

The procedure is often the shortest part. The days afterward are where most questions arise, and the three paths feel quite different.

After an injection, expect a gritty, slightly sore eye for a day, largely from the antiseptic used to clean the surface. A small red blotch on the white of the eye where the needle entered is common and harmless, fading over a week or two. Some people notice a few floaters as tiny air bubbles or drug particles drift; these settle within days. Vision may be blurry for the rest of the day, so driving home is not advisable. The Mayo Clinic notes that improvement, when it comes, is usually gradual over several weeks as fluid is reabsorbed, and the next OCT, not the mirror, tells the team whether the interval can be extended.

After laser, the eye is typically comfortable within a day. Focal laser may leave nothing noticeable. After photodynamic therapy, the infused drug leaves the skin and eyes sensitive to bright light, and people are asked to stay out of direct sunlight for a few days.

After vitrectomy with gas, the first weeks are the most demanding. Vision through the bubble is very poor at first, then a horizontal line appears and sinks lower each day as the gas shrinks. The NHS describes the bubble lasting roughly two to eight weeks depending on the gas, with face-down positioning sometimes requested for the first days after macular hole repair. Air travel and travel to high altitude are not permitted while gas remains, because the bubble expands at lower pressure and can dangerously raise eye pressure. Anesthetists must also be told about the bubble before any other surgery. Reading vision after a hole repair improves slowly, often over months, and the NHS is clear that recovery continues well beyond the point where the bubble has gone.

Risks, side effects and alternatives in plain language

Every approach carries risk, and a retina team will say so before asking for consent. Understanding the rough size and shape of those risks makes the conversation less frightening.

The most serious risk of injections is endophthalmitis, an infection inside the eye. It is rare, which is why the antiseptic preparation is done so carefully, but it is an emergency when it occurs, and its warning signs are covered later in this article. Other risks include a brief rise in eye pressure, inflammation, a scratch on the surface, and, uncommonly, a retinal tear or detachment. Because these drugs act on blood vessel signaling, the possibility of a small effect on heart and stroke risk has been studied; large reviews have not shown a consistent increase, but people with recent vascular events should tell their team, who may weigh the choice of agent accordingly.

Laser risks are mostly about location. Thermal laser creates a permanent small scotoma, a blind spot, at the treated site, and treatment near the center can reduce reading vision. Photodynamic therapy can rarely cause a sharp temporary drop in vision after treatment.

Surgery carries the risks of any intraocular operation: infection, bleeding, retinal detachment and a rise in pressure. The most predictable effect is cataract, which develops or accelerates in most eyes within a year or two of vitrectomy in people who still have their natural lens; the NHS lists this among the expected consequences rather than a rare complication.

Alternatives always exist, including doing nothing for now. Observation, low-vision rehabilitation with magnifiers and lighting, and reading support are real options rather than consolation prizes, and they are appropriate whenever the expected benefit of a procedure is small. The choice between them belongs with the treating team and the person in the chair.

How to help macular degeneration between appointments: food, smoking and self-checks

Between scans, people want something to do. The evidence supports three things clearly, and it is worth being specific about each rather than offering vague encouragement.

Stop smoking. The NHS identifies smoking as the strongest modifiable risk factor for AMD, and quitting benefits people who already have the disease, not only those hoping to avoid it. It also matters for treatment planning: beta-carotene, which was part of the original AREDS formula, is avoided in smokers because of lung cancer risk, which is one reason the second formula was redesigned.

Eat for the macula. The question about the best foods to slow macular degeneration has an honest answer: the pattern matters more than any single item. Dark leafy greens such as kale, spinach and collards are rich in lutein and zeaxanthin, the same pigments concentrated in the macula and used in the AREDS2 formula. Oily fish provides omega-3 fats; observational studies link higher fish intake with lower AMD risk, although adding omega-3 capsules in AREDS2 did not reduce progression. Colorful fruit and vegetables, nuts and whole grains round out a Mediterranean-style pattern that the NIH’s National Eye Institute describes as associated with lower risk. No food reverses existing damage.

Check your own vision. An Amsler grid, a small square of graph paper with a central dot, is the classic home tool: look at the dot with one eye at a time, reading glasses on, and note whether any lines look wavy, broken or missing. The National Eye Institute recommends this kind of regular one-eye check because the good eye masks changes in the other. Any new distortion is a reason to call, not to wait for the next scheduled appointment.

Wearing UV-protective sunglasses and keeping blood pressure and cholesterol controlled are sensible supporting measures with weaker direct evidence for the macula itself.

What people often get wrong about macular disease treatment

Myths gather around any condition that threatens sight, and some of them actively delay care. Here are the ones retina teams hear most often, set against what the evidence says.

Injections stop once the eye improves. They usually do not. The medicine wears off and the disease stays active, so most people continue on an extended schedule for years. Stopping abruptly after a good result is a common route to relapse.

Macular degeneration means going blind. AMD affects central vision, not peripheral vision. The NHS notes it does not cause total blindness; people retain the side vision needed for orientation and mobility, even in advanced disease. This matters for planning, driving assessments and low-vision support.

Laser is the old treatment, so it must be worse. Laser is the older tool, but for a leak away from the center or for polypoidal disease, it can be the more targeted one. Newer does not automatically mean better for a given anatomy.

Surgery can be done for wet AMD if injections fail. Rarely, and only for specific situations such as a large bleed. Surgery does not treat leaking vessels.

Supplements treat dry AMD. The AREDS formulas slowed progression to advanced disease by about a quarter over five years in intermediate disease, according to the NIH. They did not restore vision and showed no benefit in early disease or in people without AMD.

If one eye is fine, the other must be too. The brain fills in gaps using the stronger eye. Many people first notice wet AMD only when they happen to cover the good eye.

A procedure abroad will fix it quickly. Macular disease treatment is a relationship over time with imaging, follow-up and adjustments; a one-off intervention without ongoing review is a poor fit for how these conditions behave.

Questions to ask your care team

Retina appointments move quickly, and it is easy to leave with a plan but without understanding it. A short list of questions, written down in advance, changes the quality of the conversation. Consider asking:

• What exactly did the scan show, and which type of macular disease do I have? Ask to see the OCT image; most clinicians are happy to point out the fluid or the hole.
• Is there active leakage right now, or is this thinning that we watch?
• Why is this option being recommended over the others, and what would make you switch paths later?
• If injections are proposed, what rhythm will we follow, and how will you decide when to lengthen or shorten the interval?
• What realistic goal are we aiming for: stabilizing, improving, or slowing decline?
• If surgery is proposed, will there be a gas bubble, will I need to posture, and for how long will travel be restricted?
• What symptoms should prompt me to call before my next appointment, and what number do I call out of hours?
• How will this affect my other eye, and how should I be checking it at home?
• Are there lifestyle changes, or a specific supplement formulation, that the evidence supports at my stage?
• Should my other doctors know about this treatment, for example before other surgery or if I take blood thinners?
• Would low-vision rehabilitation help me now, regardless of the procedure?

Bring someone if you can. Dilating drops blur reading for hours, and a second pair of ears catches details. If the answer to any question is uncertain, that is not a failing; the honest answer for many people is that the team will know more after the next scan, and it is reasonable to ask when that scan will be.

When to call your doctor

Most macular conditions change slowly, but a few situations need same-day attention, and knowing the difference protects sight. Call the retina clinic or seek urgent eye care, rather than waiting for a scheduled visit, if any of the following happen.

Contact the team urgently after an injection if the eye becomes increasingly painful, red or light-sensitive, or if vision drops noticeably in the days following the procedure. These are the warning signs of endophthalmitis, an infection inside the eye, which is rare but sight-threatening and is treated as an emergency. Mild grittiness on the day of the injection is expected; worsening pain over the following days is not.

After vitrectomy, seek urgent advice for severe pain, nausea or vomiting, a rapidly worsening vision, or a new dark curtain or shadow spreading across your sight. Pain with nausea can signal dangerously high pressure from the gas bubble, and a shadow can indicate retinal detachment. Never fly or travel to high altitude with gas in the eye, and tell any anesthetist about the bubble.

At any stage, whether or not you have had treatment, new distortion where straight lines bend, a fresh dark or blank patch in the center of vision, a sudden shower of floaters, or flashes of light are reasons to be seen promptly. The NHS advises urgent review for sudden changes in vision because early treatment of wet AMD and retinal tears is linked to better outcomes than delayed treatment.

People with dry AMD should treat new distortion in either eye as a possible conversion to wet disease and call rather than wait. If you have diabetes and notice blurring that does not clear, mention it to both your eye team and your diabetes team. When in doubt, a phone call costs nothing and a delay can cost a great deal; the clinic would rather see you unnecessarily than late.

Frequently asked questions

What does macular degeneration look like from the inside?

Early on, many people notice nothing, because the other eye fills in the gaps. As it progresses, straight lines such as door frames or text may look wavy, colors can seem faded, and a blurred or blank patch settles over the center of vision while the edges stay clear. Reading and recognizing faces become harder before walking around does. Checking one eye at a time with an Amsler grid reveals changes the brain otherwise hides.

Can age-related macular degeneration be reversed?

No treatment currently reverses AMD. Wet AMD can often be controlled with anti-VEGF injections, which stop leakage and can improve vision in some eyes by drying the macula, but the underlying tendency remains and treatment is ongoing. Dry AMD is managed by monitoring and risk reduction, with specific supplements slowing progression at certain stages according to the NIH’s AREDS trials. Newer injections for geographic atrophy slow enlargement on scans rather than restoring sight.

How can I help macular degeneration myself?

Stop smoking, eat a diet rich in dark leafy greens, colorful vegetables, nuts and oily fish, wear UV-protective sunglasses, keep blood pressure controlled, and check each eye separately at home with an Amsler grid. Ask your eye clinic whether an AREDS2-type supplement is appropriate for your stage, since the evidence supports it only in intermediate or one-eye advanced disease. Attend every scheduled scan, and report new distortion promptly rather than waiting.

Do macular degeneration injections hurt?

Most people describe pressure rather than pain. Numbing drops and an antiseptic wash are applied first, and the injection itself takes seconds. The commonest complaint afterward is a gritty, sore surface for a day, usually from the antiseptic rather than the needle, and a harmless red blotch on the white of the eye that fades over one to two weeks. Increasing pain, redness or vision loss in the following days is not normal and needs an urgent call.

How long do macular degeneration injections continue?

Usually for years, and sometimes indefinitely, because the medicine wears off while the disease stays active. The NHS describes treatment starting about monthly and then being spaced out according to scans, often to every one to three months. Many teams use a treat-and-extend approach, lengthening the gap while the macula stays dry and shortening it if fluid returns. Some eyes eventually become inactive and can be monitored without injections, but that is decided by imaging, not by a fixed number.

What is the difference between wet and dry macular degeneration treatment?

Wet AMD involves leaking new blood vessels, so it is treated with anti-VEGF injections that block the leakage signal, occasionally with photodynamic therapy for specific vessel patterns. Dry AMD is a slow loss of retinal cells with no leak to block, so it is managed by monitoring, smoking cessation, diet and, at certain stages, AREDS2-type supplements. In some countries injectable complement inhibitors are approved for the late dry stage, geographic atrophy, to slow its growth.

What are the best foods to eat to help slow macular degeneration?

Dark leafy greens such as kale, spinach and collards supply lutein and zeaxanthin, the pigments concentrated in the macula. Oily fish, colorful fruit and vegetables, nuts and whole grains complete a Mediterranean-style pattern that the NIH’s National Eye Institute links with lower AMD risk. The pattern matters more than any single food, and no diet reverses existing damage. Omega-3 capsules did not slow progression in AREDS2, so eating fish is a better bet than a pill.

Is laser treatment still used for macular degeneration?

Yes, but in specific situations rather than as the first choice. Thermal laser is reserved for abnormal vessels sitting well away from the central fovea, since it destroys the retina it treats. Photodynamic therapy, a light-activated drug approach, is used for polypoidal choroidal vasculopathy and some chronic central serous disease. Focal laser remains an evidence-based option for certain patterns of diabetic macular edema, often alongside injections. For most wet AMD, injections are considered before laser.

What happens after macular hole surgery?

A gas bubble fills the eye and vision through it is very poor at first, then a line appears and drops lower each day as the bubble shrinks. The NHS says the gas absorbs over about two to eight weeks depending on the type, and some people are asked to posture face-down for part of each day early on. Flying and high altitude are unsafe until the gas has gone. Reading vision improves slowly over months, and cataract commonly develops afterward.

Who decides whether I get injections, laser or surgery?

Your retina specialist and the wider treating team, based mainly on OCT scans and, where needed, angiography. The decision hinges on whether there is active fluid, where it sits, whether anything is pulling on the retina, and whether the tissue underneath can still function. Your goals, other health conditions and ability to attend follow-up all feed in. Ask to see the scan and to hear why one path was chosen over the others.

References

• NHS: Macular hole
• NIH National Eye Institute: Age-Related Macular Degeneration (AMD)
• NIH National Eye Institute: Age-Related Eye Disease Studies (AREDS/AREDS2)
• MedlinePlus: Macular Degeneration

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.